Vetmedica, the animal health division of Boehringer Ingelheim was founded in the 1950s, and established a UK presence in 1980, initially focussing on equine respiratory disease. Since that time, Vetmedica has expanded to be the 8th largest veterinary pharmaceutical company in the UK, is also one of the fastest growing (with an average annual turnover growth of 16% per year since 1999. Vetmedica is also the fastest growing division in the Boehringer UK business.
Vetmedica promotes a wide range of both therapeutic and preventative products, dealing with both companion animals (dogs, cats, rabbits and horses) and farm animals. All Vetmedica products are sold through veterinary surgeons in the UK. We currently have no direct consumer healthcare presence.
For all enquiries regarding veterinary information in the UK, please contact us at email@example.com.
Current estimates put the UK cat and dog population at around 14.5 million. In a trend which mirrors the demographic shift in the human population, our pets are living longer, healthier lives through improved nutrition and healthcare. The trend has created a real need for effective and safe treatments for “geriatric” chronic conditions such as osteoarthritis, heart disease, and cancer.
Vetmedica’s objective is to “extend the lifespan and enhance the quality of life of companion animals”. With that in mind, the company develops and markets pharmaceuticals specifically targeted at improving the quality of life and longevity for veterinary patients. Particular areas of specialty for the company are osteoarthritis and pain relief (Metacam®), cardiovascular disease (Vetmedin®), and skin disease (Viacutan® & Dermocanis®).